Skip to main content
Premium Trial:

Request an Annual Quote

Omicia Closes $23M Series B Financing

NEW YORK (GenomeWeb) – Omicia said today that it has completed a $23 million Series B financing round.

Several new investors participated in the round including UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, and a large undisclosed genomics investor. Existing investors Artis Ventures, Acadia Woods Partners, and Buchanan Investments also participated in the financing.

Omicia, based in Oakland, California, will use the proceeds to accelerate product development and expand its sales and marketing operations. In addition, the company plans to extend variations of its flagship Opal Clinical platform for use in new geographies and new verticals, including life science research, clinical trials support, populations health management, and consumer applications.

Omicia's software provides scalable next-generation sequence interpretation and reporting capabilities to drive improved clinical outcomes, and enables users to scale production in a HIPAA-compliant, cloud-enabled environment. The software also leverages a deep variant data warehouse to deliver high-throughput results to assist lab partners with automated diagnostic reporting, the company said.

"With new investment from one of the nation's leading health systems, a premier life sciences company, and China's largest insurance company, we are well positioned to expand our team and extend our technologies, products, and services into new markets," Omicia CEO Matt Tindall said in a statement. "As evidenced by the work we're doing with Genomics England, the world's leading national genome project, Omicia is filling a critical gap between sequencing tools and clinical decision making, delivering on the promise of precision medicine."

Along with competing informatics firm Congenica, Omicia inked a contract last year with Genomics England to interpret genomic data from the first 8,000 patients participating in the UK's 100,000 Genomes Project.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.